Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBIscintigraphy and other biochemical markers of disease activity

被引:9
作者
Alexandrakis, MG
Kyriakou, DS
Passam, FH
Malliaraki, N
Vlachonikolis, IG
Karkavitsas, N
机构
[1] Univ Hosp Heraklion, Dept Hematol, Iraklion, Crete, Greece
[2] Univ Hosp Thessalia, Dept Hematol, Thessalia, Greece
[3] Univ Hosp Crete, Dept Clin Biochem, Iraklion, Greece
[4] Med Sch Crete, Dept Biostat, Iraklion, Greece
[5] Univ Hosp Crete, Dept Nucl Med, Iraklion, Greece
关键词
N-telopeptide; Tc-99m sestaMIBI; TNF; multiple myelonta; bone resorption;
D O I
10.1002/hon.700
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Urinary cross-linked N-telopeptide of type I collagen (NTx) has been reported to be a sensitive and specific marker of bone resorption in multiple myeloma (MM). In this study, we measured the levels of NTx in 30 newly diagnosed MM patients and 25 controls. We examined its association with the overall score of skeletal involvement measured by Tc-99m-MIBI scintigraphy and other biochemical markers of bone disease (tumour necrosis factor a (TNF-a), serum calcium and creatinine). We further studied the correlation of NTx with the stage of disease (according to Durie-Salmon criteria) and bone marrow infiltration by plasma cells. High levels of NTx, bone marrow infiltration, TNF-alpha, calcium and creatinine were noted at advanced stages of disease (p < 0.05). NTx and TNF-a were found at significantly higher concentrations in patients with a high overall score (3 and 4) in Tc-99m-sestaMIBI in comparison to a low score (0, 1 and 2; p < 0.05). Positive correlations were found between NTx and TNF-a, as well as between bone infiltration and TNF-a or calcium. In conclusion, NTx is a useful marker for the monitoring of bone resorption in MM and correlates with imaging findings on Tc-99m-sestaMIBI and other biochemical markers of disease activity. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:17 / 24
页数:8
相关论文
共 27 条
[21]   Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up [J].
Pace, L ;
Catalano, L ;
Del Vecchio, S ;
Di Gennaro, F ;
De Renzo, A ;
Sica, G ;
Califano, C ;
Tedesco, N ;
Borrelli, G ;
Rotoli, B ;
Salvatore, M .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (03) :304-312
[22]   Cell biology of the osteoclast [J].
Roodman, GD .
EXPERIMENTAL HEMATOLOGY, 1999, 27 (08) :1229-1241
[23]   Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density [J].
Schneider, DL ;
BarrettConnor, EL .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (11) :1241-1245
[24]   Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation [J].
Svaldi, M ;
Tappa, C ;
Gebert, U ;
Bettini, D ;
Fabris, P ;
Franzelin, F ;
Osele, L ;
Mitterer, M .
ANNALS OF HEMATOLOGY, 2001, 80 (07) :393-397
[25]   Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma [J].
Terpos, E ;
Palermos, J ;
Tsionos, K ;
Anargyrou, K ;
Viniou, N ;
Papassavas, P ;
Meletis, J ;
Yataganas, X .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2000, 65 (05) :331-336
[26]  
Witzig TE, 1996, BLOOD, V88, P1780
[27]   EVIDENCE THAT TUMOR-NECROSIS-FACTOR PLAYS A PATHOGENETIC ROLE IN THE PARANEOPLASTIC SYNDROMES OF CACHEXIA, HYPERCALCEMIA, AND LEUKOCYTOSIS IN A HUMAN TUMOR IN NUDE-MICE [J].
YONEDA, T ;
ALSINA, MA ;
CHAVEZ, JB ;
BONEWALD, L ;
NISHIMURA, R ;
MUNDY, GR .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (03) :977-985